Kevin Damour - 28 Jun 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role: Chief Scientific Officer
Signature: /s/ Kevin D'Amour
Issuer symbol: ERNA
Transactions as of: 28 Jun 2022
Net transactions value: -$3,363
Form type: 4
Filing time: 29 Jun 2022, 20:01:50 UTC
Previous filing: 17 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ERNA	Common Stock	Options Exercise		+17,573			17,573	28 Jun 2022	Direct	F1
transaction	ERNA	Common Stock	Tax liability	$3,363	-6,077	-35%	$0.5534^*	11,496	28 Jun 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ERNA	Restricted Stock Units	Options Exercise	$0	-17,573	-25%	$0.000000	52,717	28 Jun 2022	Common Stock	17,573		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit converts into one share of common stock.
F2	On June 28, 2021, the reporting person was granted 70,290 restricted stock units, vesting in four substantially equal installments beginning on the first anniversary of the grant date.